Pancreatic Neoplasms: all 3,311 studies

Page 15 of 34. Open to participants first (911), then studies with results posted, then the rest; newest registration first within each.

• A Study Comparing Restrictive and Liberal Fluid Therapy During Pancreatecoduodenectomy SurgeryCompletedNCT07072897Not applicable
• Diagnostic Consistency of GLIM and PG-SGA for Malnutrition in Pancreatic CancerCompletedNCT07057895Not applicable
• Sequential Nutrition Intervention for Pancreatic Cancer Patients Undergoing CyberKnife RadiotherapyCompletedNCT07057843Not applicable
• Prediction Model of Pancreatic Neoplasms in CP Patients With Focal Pancreatic LesionsCompletedNCT07045181
• Laparotomy, Laparoscopy, da Vinci SystemCompletedNCT07034495
• A Phase II Study to Evaluate GFH375 in Patients With KRAS G12D Mutant Metastatic Pancreatic CancerWithdrawnNCT07026916Phase 2
• A Study of Narmafotinib Given in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic CancerActive, not recruitingNCT07026279Phase 1/2
• A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D MutationActive, not recruitingNCT07023731Phase 1/2
• Surgical Approach for Adenocarcinoma of the Pancreas With Synchronous Liver MetastasesCompletedNCT06980792
• ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid TumorsCompletedNCT06973161
• Multimodal Managements for Metastatic Pancreatic Cancer.CompletedNCT06967233
• Clinical Validation of a Blood Biomarker Test to Detect Early-Stage Pancreatic Cancer (VERIFI)CompletedNCT06947395
• Clinical Validation of Immunovia Next-Generation Blood Biomarker Test to Detect Early-Stage Pancreatic CancerCompletedNCT06947382
• SENECA: First Line metaStatic pancrEatic caNcer Primary and Distant (if Oligometastatic) lEsion direCted rAdiotherapyActive, not recruitingNCT06946420Phase 3
• LIQUID BIOPSY FOCUSING ON CIRCULATING TUMOR CELLS AND CIRCULATING TUMOR DNA AS PRECISION MEDICINE IN GASTROINTESTINAL TUMORSActive, not recruitingNCT06940778
• Multimodal Therapy Impact on Pancreatic Cancer SurvivalActive, not recruitingNCT06938906
• Does Recurrent Pancreatic Cancer Really Have Similar Outcome Compared With Primary Metastatic Pancreatic Cancer?CompletedNCT06921252
• Clinico-demographic Profile of the Patient With Pancreaticobiliary Malignancy Undergoing ERCP in a Tertiary Care Center of NepalCompletedNCT06888401
• The Significance and Indications of Surgery for Synchronous Liver Metastatic Pancreatic CancerActive, not recruitingNCT06873178
• MRD in PAAD Adjuvant TherapyActive, not recruitingNCT06867146Not applicable
• IMPact of AerobiC Exercise in Addition to Nutritional Treatment on Quality of Life After PancreatectomyActive, not recruitingNCT06858631Not applicable
• Effects of Aromatherapy With Essential Oils on Anxiety and Depression in Perioperative Patients With Pancreatic CancerCompletedNCT06833658Not applicable
• PARA (Pancreatic Adenocarcinoma Etiology: Role of Asbestos) Study of Risk Factors for Exocrine Pancreatic Neoplasms.Active, not recruitingNCT06815172
• Investigation of the Optimal Duration of Neoadjuvant Therapy for Resectable Pancreatic CancerCompletedNCT06809374
• Validation Study on the Removal of EpCAM-positive Tumour Cells From Blood Collected During Tumour Surgery Using Catumaxomab/Catuvab DeviceCompletedNCT06789224Not applicable
• Study of NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Pancreatic CancerActive, not recruitingNCT06783140Phase 2/3
• Adebrelimab Combined With Irinotecan Liposomal (II), Oxaliplatin, and 5-FU/LV Conversion Therapy for Locally Advanced Pancreatic CancerActive, not recruitingNCT06766019Phase 2
• Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic CancerActive, not recruitingNCT06736717Phase 1/2
• The Future Management of Patients With Neoplasms of the Gastro-intestinal TractActive, not recruitingNCT06728358Not applicable
• Physical Activity and Nutrition to Halt Elevated Risk in the Pancreas Interception CenterActive, not recruitingNCT06712797Not applicable
• Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)Active, not recruitingNCT06710132Phase 1/2
• A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal MalignanciesWithdrawnNCT06690281Phase 2
• Open Versus Total Laparoscopic PancreaticoduodenectomyCompletedNCT06661135Not applicable
• Fecal and Oral Microbiota Between Pancreatic Cancer and Benign/Low-grade Malignant Tumor PatientsCompletedNCT06659237
• EUS-guided Choledochoduodenostomy vs ERCP as First Line in Malignant Distal Obstruction (CARPEDIEM Trial)SuspendedNCT06653192Not applicable
• Research of the Application of Pancreatic Cancer Screening Artificial Intelligence Model "PANDAPro"Active, not recruitingNCT06643715Not applicable
• Differentiation Benign and Malignant Pancreatic LesionsCompletedNCT06641947
• New Technique of Pancreaticojejunostomy During Whipple OperationCompletedNCT06630910Not applicable
• STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and MelanomaWithdrawnNCT06626256Phase 1
• Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)Active, not recruitingNCT06625320Phase 3
• Dose-Escalation of MNPR-101-PCTA-177Lu in Solid TumorsActive, not recruitingNCT06617169Phase 1
• Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal AdenocarcinomaActive, not recruitingNCT06608927Phase 3
• A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid TumorsActive, not recruitingNCT06607185Phase 1
• Certepetide Phase 1b/2a Continuous Infusion Trial in mPDACWithdrawnNCT06592664Phase 1/2
• Enhanced Assistance During Radiotherapy for Unmet Essential NeedsCompletedNCT06582849Not applicable
• Pancreatic Fistula After Minimally Invasive EnucleationCompletedNCT06557408
• The Effect of Albumin Value, HALP Score, and LCR Value on Predicting Survival and Recurrence in Patients With Pancreatic AdenocarcinomaCompletedNCT06553040
• Palliative Care Consultation to Improve Communication for Patients Considering Surgery for a Pancreatic NeoplasmWithdrawnNCT06545344Not applicable
• Clinical Study Evaluating the Effect of LosartanCompletedNCT06539806Not applicable
• CEB-01 in Locally Resectable Pancreatic CancerActive, not recruitingNCT06538857Early Phase 1
• Oxaliplatin Combined With Irinotecan Liposome Injection II Through Hepatic Artery Infusion (HAIC) Followed by 5-FU/LV (HAIC) or Tegorgor Oral Combination Therapy for Hepatic Metastasis of Pancreatic CancerCompletedNCT06538623Phase 2
• An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Modified FOLFIRINOX (mFFX) or Gemcitabine Plus Nab-paclitaxel (GnP) Therapy as First-line Treatment in Patients With Metastatic Pancreatic CancerCompletedNCT06538207Phase 1
• An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic CancerActive, not recruitingNCT06532344Phase 1
• A PhaseⅠStudy of ONO-7475 in Combination With ONO-4538 and Gemcitabine Plus Nab-paclitaxel (GnP), the Standard of Care, and ONO-7475 in Combination With GnP in Patients With Pancreatic CancerActive, not recruitingNCT06532331Phase 1
• Study of IPMN Progression Prevention With Tocotrienol (SIPP-T3)Active, not recruitingNCT06519097Phase 2
• Evaluate Efficacy of Devimistat in Combination With mFFX in 2nd Line Patients With Metastatic Pancreatic CancerWithdrawnNCT06518538Phase 2
• A Trial of Gemcitabine, Pembrolizumab and IMM-101 as First Line Treatment in Patients With Metastatic Pancreatic CancerWithdrawnNCT06498518Phase 2
• IX001 TCR-T In the Treatment of Advanced Pancreatic Cancer and Colorectal Cancer Induced by KRAS MutationsWithdrawnNCT06487377Phase 1
• Correlation of Portal and Peripheral Venous ctDNA in Pancreatic AdenocarcinomaCompletedNCT06478056Not applicable
• Nimotuzumab Plus NALIRIFOX in Locally Advanced Pancreatic CancerActive, not recruitingNCT06429904Phase 2
• Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal AdenocarcinomaWithdrawnNCT06398587Phase 2
• EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal AdenocarcinomaCompletedNCT06390059Phase 2
• Using an End-of-life Conversation Game to Engage Patients With Cancer in Advance Care Planning: Phase 2CompletedNCT06384417Not applicable
• Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic CancerActive, not recruitingNCT06381154Phase 2
• Risk Factors of Postoperative Complications and Survival Rate in Pancreatic Ductal Adenocarcinoma PatientsCompletedNCT06378853
• Irreversible Electroporation & Pembro Immunotherapy in Locally Advanced Pancreatic CancerCompletedNCT06378047Phase 1
• A Retrospective Study for Nimotuzumab Plus Postoperative Adjuvant Chemotherapy for Resectable Pancreatic CancerCompletedNCT06363084
• A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)Active, not recruitingNCT06360354Phase 1
• Prophylactic Administration of Neulapeg (Pegteograstim) in Patients With Locally Advanced or Metastatic Pancreatic Cancer Receiving the Modified FOLFIRINOXActive, not recruitingNCT06353581Phase 2
• Glucose Control Through a Bihormonal Artificial Pancreas in Patients After Total PancreatectomyActive, not recruitingNCT06346366Phase 3
• Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid TumorsActive, not recruitingNCT06337084Phase 1
• A Deep Learning Radiomics Model for Predicting Occult Peritoneal Metastases of Pancreatic AdenocarcinomaCompletedNCT06336694
• A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid TumorsTerminatedNCT06336148Phase 1
• Epigenomic and Machine Learning Models to Predict Pancreatic CancerActive, not recruitingNCT06334458Not applicable
• Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid TumorsActive, not recruitingNCT06334432Phase 1/2
• Cancer Coaching and Remote Education for Self-Empowerment (CARES) StudyCompletedNCT06323291Early Phase 1
• Permanent Celiac Plexus Block: Comparison of Pain Score in Unilateral and Bilateral Posterior Percutaneous ApproachCompletedNCT06316908Phase 4
• First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC PatientsActive, not recruitingNCT06313970Phase 2
• Clinician Decision Making Regarding Surveillance for Low-risk Intraductal Papillary Mucinous Neoplasms of The PancreasCompletedNCT06311032
• WATD and Cancer-Related Fatigue: A Study For Patients Undergoing Anti-Cancer TreatmentActive, not recruitingNCT06291324
• A Clinical Study of AL2846 Capsule Combined With Gemzar Injection in the Treatment of Advanced Pancreatic CancerCompletedNCT06278493Phase 1/2
• Study of IK-595 in RAS- or RAF-altered Advanced TumorsTerminatedNCT06270082Phase 1
• A Study to Understand Participant's Experiences in Gastro-enteropancreatic Neuroendocrine Tumors (GEP-NETs) and AcromegalyCompletedNCT06253897
• Statin Addition to Chemotherapy for Advanced Pancreatic CancerCompletedNCT06241352Phase 2
• A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid TumorsActive, not recruitingNCT06238479Phase 1
• FL118 for Treating Patients With Advanced Pancreatic Ductal AdenocarcinomaWithdrawnNCT06206876Phase 1
• A Trial of YL-13027 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Refractory Metastatic Pancreatic CancerTerminatedNCT06199466Phase 1
• Stereotactic Body Radiotherapy Combined With PD-1 Blockers for Locally Advanced or Locally Recurrent Pancreatic CancerCompletedNCT06195254
• Choices About Genetic Testing And Learning Your Risk With Smart TechnologyCompletedNCT06184867Not applicable
• Mobile Weight Loss Intervention for Adolescent and Young Adult Cancer SurvivorsCompletedNCT06171945Not applicable
• A Study of Glipizide to Treat High Blood Sugar in People With Pancreatic CancerActive, not recruitingNCT06168812Phase 2
• An Exploration of Candidates for Neoadjuvant Treatment in Resectable Pancreatic CancerCompletedNCT06129812
• Safety, Tolerability, Pharmacokinetics, Radiation Dosimetry, and PET Imaging Properties of 89Zr-labeled hNd2 (NMK89) in Patients With Pancreatic CancerCompletedNCT06129422Phase 1
• The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic CancerActive, not recruitingNCT06115499Phase 2/3
• CAPEcitabine eXtension of Adjuvant Therapy for Pancreatic Adenocarcinoma: (CAPE-X)WithdrawnNCT06110598Phase 2
• An Observational Study to Learn More About the Impact of Gadoxetate Sodium-Enhanced Magnetic Resonance Imaging (EOB-MRI) When Used to Diagnose the Spread of Cancer From the Pancreas to the Liver in Japanese People Under Real-World ConditionsCompletedNCT06106568
• A Study of HY-0102 in Patients With Advanced Solid TumorsStatus unknownNCT06094777Phase 1
• NEO-adjuvant Chemo-immunotherapy in Pancreatic CancerActive, not recruitingNCT06094140Phase 2
• The Significance of Postoperative Muscle Wasting in Pancreatic CancerCompletedNCT06093009
• A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6TerminatedNCT06091930Phase 1

← Pancreatic Neoplasms overview